As Philadelphia enters weeks of 90-degree days, the city is faced with two crises at once: heat exposure and the coronavirus.
NextHealth PHL covers the healthcare industry in Philadelphia and the work of scientists, doctors, and healthcare companies in Cellicon Valley. NextHealth PHL puts a special emphasis on healthcare news in the vibrant cell and gene therapies sector.
Researchers at MossRehab are studying whether the technology can help rewire patients’ brains to alleviate unexplained limb pain in amputees.
The Series D financing will enable the Mount Laurel company to bring its FDA-approved Optimizer Smart therapy to millions of U.S. patients with chronic heart failure.
The local company has invented a chromatography technique that could save biotech companies millions of dollars.
During Cancer Screen Week, the American Cancer Society’s Carmen Guerra talked to us about how to ensure equal access to preventative cancer screenings.
A new study from researchers at Drexel University found that narrative posts on Instagram may be an effective tool in curbing misinformation about vaccines.
Through a partnership with the Children’s Hospital of Philadelphia, Airthinx is also bettering how we monitor and treat young children with asthma.
Here’s what Temple and other Philadelphia colleges and universities are doing to put more black men in white coats.
Using innovative tools like blockchain, this local clinical research service organization is helping companies bring new therapies to patients sooner.
A new study by Jefferson researchers used artificial intelligence on images of thyroid growths to predict the risk of cancer.
MossRehab is the first in the region to use the SPRINT endura Peripheral Nerve Stimulation (PNS) System, a promising new therapy for acute and chronic pain.
Cognizance has developed a diagnostic test to accurately detect the difference between seizures and other neurological conditions.
Penn’s Tom Cappola tells us about the latest clinical trials and medical breakthroughs to be announced during AHA’s Scientific Sessions.
The program supports companies seeking to improve a civil service or the health of a population through technology with an eye on global expansion.
Zynerba is testing a CBD gel for the treatment of behavioral symptoms associated with Fragile X Syndrome, the most common genetic cause of autism.
Penn’s Kiran Musunuru talks to us about the technology that has been both praised and criticized for its ability to alter human DNA and potentially cure disease.